Alkermes Plc(NASDAQ) ALKS

Market Cap$8.42B

Since IPO (1991)+833%

5 Year+101%

1 Year+93%

1 Month-8%

$48.25

-4.46%

-2.25Today

Alkermes Plc last closing stock price
Metric	Price	Date
Last close	USD 50.50	2026-07-28

Alkermes Plc stock price return by period
Period	Price return	Price at period start	Period start date
1 week	-4.45%	USD 52.85	2026-07-21
1 month	-8.32%	USD 55.08	2026-06-26
3 month	+49.81%	USD 33.71	2026-04-29
Year to date	+80.49%	USD 27.98	2025-12-31
1 year	+93.12%	USD 26.15	2025-07-28
3 year	+78.45%	USD 28.30	2023-07-28
5 year	+100.79%	USD 25.15	2021-07-29
Since inception	+833.14%	USD 5.41	1991-07-16

Alkermes Plc Financials at a Glance

Market Cap

$8.42B

Revenue (TTM)

$1.67B

Net Income (TTM)

$66.12M

EPS (TTM)

$0.90

P/E Ratio

56.14

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$48.25

Volume

4,149,634

Open

$50.50

Price

$48.25

Volume

4,149,634

Open

$50.50

Previous Close

$48.34

Daily Range

$47.66 - $50.72

52-Week Range

$25.17 - $55.67

Estimated Earnings Date

Oct 27, 2026

Dividend

$0.00

Beta (Volatility)

0.60 (Low)

Price

$48.25

Volume

4,149,634

Open

$50.50

Previous Close

$48.34

Daily Range

$47.66 - $50.72

52-Week Range

$25.17 - $55.67

Estimated Earnings Date

Oct 27, 2026

ALKS News

A scientist looking through a microscope.

Page 1

ALKS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Alkermes Plc

Alkermes plc is a global biopharmaceutical company headquartered in Ireland, focusing on developing and commercializing innovative medicines in neuroscience. Its portfolio primarily addresses mental health conditions, including schizophrenia, bipolar I disorder, alcohol dependence, and opioid dependence. With manufacturing facilities in Ohio and significant R&D investments, Alkermes is committed to addressing unmet medical needs through its advanced drug delivery technologies.

Products and Services

ARISTADA®: An extended-release injectable treatment for schizophrenia.

LYBALVI®: A daily oral medication for schizophrenia and bipolar I disorder.

VIVITROL®: Injectable therapy for alcohol and opioid dependence, offering extended-release benefits.

INVEGA SUSTENNA®, INVEGA TRINZA®, INVEGA HAFYERA®: Schizophrenia treatments utilizing Alkermes' technologies under license to Janssen.

VUMERITY®: An oral medication for multiple sclerosis, commercialized by Biogen incorporating Alkermes' technology.

What Makes Alkermes plc Special

Alkermes plc distinguishes itself through its proprietary drug delivery technologies, NanoCrystal® and LinkeRx®, which enhance drug bioavailability and patient compliance. This technological edge supports its focus on CNS disorders and strengthens its position in the market. The company's strategic ventures into oncology and its robust R&D pipeline underscore its commitment to innovation and growth.

Five Things You Need to Know

Alkermes is a leader in CNS disorder treatments, addressing diseases like schizophrenia and bipolar I disorder.

The company heavily invests in R&D to maintain a robust pipeline of neurological drug candidates.

Alkermes holds strategic collaborations for its technologies, notably with Janssen and Biogen.

Alkermes generates revenue from proprietary products and licensed technologies, ensuring diverse income streams.

The company's proprietary NanoCrystal® and LinkeRx® technologies provide competitive advantages in drug delivery.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

2,050

CEO

Richard F. Pops

Website

www.alkermes.com

Headquarters

Dublin, DU D04 C5Y6, IE

ALKS Financials

Key Financial Metrics (TTM)

Gross Margin

60.70%

Operating Margin

7.03%

Net Income Margin

3.97%

Return on Equity

3.72%

Return on Capital

13.44%

Return on Assets

1.51%

Earnings Yield

1.78%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$8.42B

Shares Outstanding

166.68M

Volume

4.15M

Avg. Volume

2.25M

Financials (TTM)

Gross Profit

$1.01B

Operating Income

$117.26M

EBITDA

$116.49M

Operating Cash Flow

$251.18M

Capital Expenditure

-$29.53M

Free Cash Flow

$221.65M

Cash & ST Invst.

$691.63M

Total Debt

$1.57B

Alkermes Plc Performance Analysis

Alkermes Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	USD 1,111,795,000	-5.3%
2023	2023-12-31	USD 1,663,405,000	49.6%
2024	2024-12-31	USD 1,557,632,000	-6.4%
2025	2025-12-31	USD 1,475,899,000	-5.2%

Alkermes Plc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	0.9%
Q4	2025-12-31	-2.4%
Q1	2026-03-31	2.2%
Q2	2026-06-30	26.2%

Alkermes Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	USD -0.97	223.0%
2023	2023-12-31	USD 2.10	N/A
2024	2024-12-31	USD 2.17	3.5%
2025	2025-12-31	USD 1.43	-34.0%

Alkermes Plc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2025-09-30	-5.8%
Q4	2025-12-31	-40.8%
Q1	2026-03-31	-237.9%
Q2	2026-06-30	100.8%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

$496.01M

+27.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

$8.42B

N/A

Market Cap/Employee

$4.11M

N/A

Employees

2,050

N/A

Net Income

$501.00K

-99.4%

EBITDA

-$47.23M

-141.9%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

$691.63M

-31.9%

Total Debt

$1.57B

+2063.7%

Accounts Receivable

$456.48M

+28.6%

Inventory

$298.96M

+55.8%

Long Term Debt

$1.54B

+2223.6%

Short Term Debt

$33.98M

+425.8%

Return on Assets

1.51%

N/A

Return on Invested Capital

3.14%

N/A

Free Cash Flow

$137.04M

-0.1%

Operating Cash Flow

$145.18M

-3.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

PTGXProtagonist Therapeutics, Inc.

PTGXProtagonist Therapeutics, Inc.$133.00-2.81%

TGTXTG Therapeutics, Inc.

TGTXTG Therapeutics, Inc.$53.48-2.53%

KYMRKymera Therapeutics, Inc.

KYMRKymera Therapeutics, Inc.$105.25-0.86%

PCVXVaxcyte, Inc.

PCVXVaxcyte, Inc.$52.98-2.97%

ACLXArcellx, Inc.

ACLXArcellx, Inc.$115.07+0.02%

PTCTPTC Therapeutics, Inc.

PTCTPTC Therapeutics, Inc.$74.49-1.19%

ARWRArrowhead Pharmaceuticals, Inc.

ARWRArrowhead Pharmaceuticals, Inc.$86.22+0.51%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

SOFISoFi Technologies

SOFISoFi Technologies$15.25-0.09%

INTCIntel

INTCIntel$81.88-0.05%

NVDANvidia

NVDANvidia$190.01-0.04%

TQQQProShares Trust - ProShares UltraPro Qqq

TQQQProShares Trust - ProShares UltraPro Qqq$57.75-0.06%

FFord Motor Company

FFord Motor Company$15.28+0.02%

NOKNokia

NOKNokia$8.41-0.06%

JBLUJetBlue Airways

JBLUJetBlue Airways$5.72-0.05%

Questions About ALKS

What is the current price of Alkermes Plc?

Alkermes Plc is trading at $48.34 per share.

What is the 52-week range for Alkermes Plc?

Over the past 52 weeks, Alkermes Plc has traded between $25.17 and $55.67.

How much debt does Alkermes Plc have?

As of the most recent reporting period, Alkermes Plc reported total debt of $1.57B.

How much cash does Alkermes Plc have on hand?

Alkermes Plc reported $511.53M in cash and cash equivalents in its most recent financial results.

What is Alkermes Plc’s dividend yield?

Alkermes Plc does not currently have a dividend yield.

Alkermes Plc(NASDAQ) ALKS

Alkermes Plc Financials at a Glance

ALKS News

5 Best Biotech ETFs for 2026 and How to Invest

Alkermes Q2 Sales Up 14 Percent

Alkermes Plc EPS Soars Past Forecasts

Alkermes' Q3 Proprietary Sales Soar 18%

Why Alkermes Stock Is Sinking Today

Why Alkermes Stock Is Jumping Today

Why Alkermes Stock Blasted 15% Higher Today

Why Alkermes Stock Is Sinking Today

ALKS: Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Alkermes Plc

Products and Services

What Makes Alkermes plc Special

Five Things You Need to Know

ALKS Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Alkermes Plc Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About ALKS

What is the current price of Alkermes Plc?

What is the 52-week range for Alkermes Plc?

How much debt does Alkermes Plc have?

How much cash does Alkermes Plc have on hand?

What is Alkermes Plc’s dividend yield?

Premium Investing Services